On July 23 and July 23, 2026 from 8:00 am to 4:30 pm EST, the Food and Drug Administration, HHS, will be holding a public advisory meeting of the Pharmacy Compounding Advisory Committee in Silver FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies Industry Update: Interim 503A and 503B Bulks Lists New Revisions Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg #